RYTM vs. ARVN, MORF, AKRO, PLRX, ANNX, ROIV, ELAN, ASND, LEGN, and CERE
Should you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Arvinas (ARVN), Morphic (MORF), Akero Therapeutics (AKRO), Pliant Therapeutics (PLRX), Annexon (ANNX), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), and Cerevel Therapeutics (CERE). These companies are all part of the "pharmaceutical preparations" industry.
Arvinas (NASDAQ:ARVN) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings.
Arvinas currently has a consensus target price of $61.13, suggesting a potential upside of 84.80%. Rhythm Pharmaceuticals has a consensus target price of $54.33, suggesting a potential upside of 45.55%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Arvinas is more favorable than Rhythm Pharmaceuticals.
95.2% of Arvinas shares are owned by institutional investors. 5.2% of Arvinas shares are owned by insiders. Comparatively, 5.6% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Rhythm Pharmaceuticals received 104 more outperform votes than Arvinas when rated by MarketBeat users. Likewise, 65.71% of users gave Rhythm Pharmaceuticals an outperform vote while only 65.40% of users gave Arvinas an outperform vote.
In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than Arvinas. MarketBeat recorded 8 mentions for Rhythm Pharmaceuticals and 6 mentions for Arvinas. Rhythm Pharmaceuticals' average media sentiment score of 1.07 beat Arvinas' score of 0.70 indicating that Arvinas is being referred to more favorably in the media.
Arvinas has a net margin of -185.09% compared to Arvinas' net margin of -297.91%. Rhythm Pharmaceuticals' return on equity of -64.79% beat Arvinas' return on equity.
Rhythm Pharmaceuticals has lower revenue, but higher earnings than Arvinas. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.
Arvinas has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500.
Summary
Arvinas beats Rhythm Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rhythm Pharmaceuticals Competitors List
Related Companies and Tools
